Πλοήγηση ανά Θέμα "GROWTH-FACTOR RECEPTOR"
Αποτελέσματα 1-6 από 6
-
Chromogenic in situ Hybridization Analysis of EGFR Gene Copies in Colon Adenocarcinoma Based on Intra-Operative Imprints and Tissue Microarrays
(2009)Background: Although Epidermal Growth Factor Receptor (EGFR) over expression is a frequent event in colon adenocarcinoma (CA), identification of EGFR gene deregulation mechanisms - combined to k-ras mutations - remains the ... -
Early systemic sclerosis-opportunities for treatment
(2015)Systemic sclerosis (SSc) is characterized by microvasculopathy (Raynaud's phenomenon and fibrointimal proliferation), presence of autoantibodies and collagen deposition in skin (scleroderma) and internal organs. ... -
Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression
(2001)In endometrial tissues, malignant change may be accompanied by a loss of hormone dependence which is, usually, reflected in a parallel loss of oestrogen and progesterone receptors (ER and PR). In this study, the steroid ... -
Molecular Pathogenesis of Non Muscle-Invasive Bladder Cancer: Implications for Novel Targeted Therapies
(2011)Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnosed with non-muscle invasive disease. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic ... -
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation
(2006)Background: Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown. Patients and Methods: ... -
Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise
(2010)Importance of the field: Platinum-based chemotherapy is considered the standard-of-care first-line therapy for metastatic bladder cancer. Despite the initial high response rate, the vast majority of patients eventually ...